ClinicalTrials.govpublic full text
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
multiple myeloma, hematologic diseases, neoplasms, isatuximab, cyclophosphamide, dexamethasone, bortezomib, lenalidomide, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 914346
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.